Breaking news from #ELCC2025: It was great to share results from the eyonis LCS REALITY pivotal study with the ELCC community today, during the poster session! Our poster more specifically focused on eyonis LCS performance in detecting early-stage lung cancer. Many thanks to Ray Osarogiagbon first author, and Pr. REVEL Marie-pierre for visiting us, and to all who attended the poster presentation this afternoon! Big kudos to the Median eyonis team, Thomas Bonnefont , Valérie Bourdès, MD, MPH Antoine Disset, PhD Benoit HUET and Stefania Baraghini Our poster is already available here: https://lnkd.in/dzgz_zy3 Stay tuned for further developments! #eyonis #Ai4health #lungcancerscreening #median
关于我们
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis?, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).
- 网站
-
https://www.mediantechnologies.com/
Median Technologies的外部链接
- 所属行业
- 软件开发
- 规模
- 201-500 人
- 总部
- Valbonne
- 类型
- 上市公司
- 创立
- 2002
- 领域
- clinical trials、imaging CRO、oncology clinical trials、iRECIST、RECIST 1.1、iBiopsy、Artificial Intelligence、Deep Learning、Big Data、Cloud Computing、Immuno-oncology、Liver diseases、Image processing、Software as Medical Device、Data Science、eyonis和Medical image processing
地点
Median Technologies员工
-
Jean-Christophe Montigny
Chief Financial Officer
-
Thomas Bonnefont
Chief Operating Officer & Chief Commercial Officer - eyonis oncology - Median Technologies
-
Qais Marafie
Chief Executive Officer at KLSC
-
Benoit HUET
Artificial Intelligence & Data Science Director – eyonis at Median Technologies
动态
-
??Unlocking Body Composition’s Potential in Oncology Trials?? Research over the past two decades has shown that body composition is a key imaging biomarker?in oncology.?It can refine patient stratification, predict treatment response, and transform cancer research and care. So why is it still underutilized in oncology trials? In collaboration with?Syneos Health, our latest white paper explores how to accelerate its adoption—tackling clinical evidence, accessibility, usability, and cost-effectiveness. Backed by?scientific support, it makes a compelling case for implementation. ???Swipe left to learn more ???The full white paper is available here: https://lnkd.in/e9EiBK5X A huge thank you to the Syneos Health team—?Catarina Alves Ribeiro,?Senior Medical Director, and?Jane Bentley,?VP Clinical Strategy Lead, Oncology, and to the Median team—?hubert beaumont, Lead Clinical Scientist, and?Antoine IANNESSI,?VP Medical Affairs—for their invaluable contributions to this work! #Oncology #ClinicalTrials #BodyComposition #CancerResearch #PersonalizedMedicine
-
Table ronde : L’IA au service des essais cliniques – Défis et r?le de la France dans l’innovation????? ? L’intelligence artificielle révolutionne la recherche clinique en accélérant le développement des traitements et en optimisant la sélection des patients. Mais quels sont les enjeux scientifiques, éthiques et réglementaires ? Quelle place pour la France dans cette transformation ? ? ???Jeudi 10 avril à 19h ???Campus Edhec Paris ??Un événement organisé en collaboration avec la Chaire Management in Innovative Health de l’EDHEC Business School ????Evènement en fran?ais ? Nous aurons le plaisir d’accueillir des experts issus de divers horizons : ???Caroline Beaufour – Responsable Innovation - Développement Clinique, Servier ???Olivier Clatz – Program Manager - Digital Ségur, Ministère des Solidarités et de la Santé ???David Gruson – Directeur de Programme Santé à Domicile, La Poste Santé & Autonomie / Fondateur Ethik-IA ???Antoine IANNESSI – VP des Affaires Médicales, Median Technologies ???Vassili Soumelis – Chief Medical Officer, OWKIN ? Une discussion essentielle pour comprendre comment l’IA fa?onne l’avenir des essais cliniques ! ?? Il ne reste plus que quelques places disponibles ! ????Inscription gratuite ici????https://lnkd.in/ebFZfVGu ? #TableRonde #IA #Santé #Innovation #EssaisCliniques #ManagementInnovativeHealth
-
-
?? Artificial intelligence is a quick detective, non-invasive & high-performing ? support for early stages lung cancer screening (1). ??That's why Median’s eyonis? team mission is to develop a groundbreaking end-to-end AI/ML tech-based CADe/CADx SaMD to assist radiologists and healthcare professionals in the early detection, localization, characterization of lung ?? & liver cancers, empowering them in making timely and accurate diagnoses. ? 1. Artificial Intelligence and its future potential in lung cancer screening. (2020). EXCLI Journal, 19, 1552–1562. https://lnkd.in/ds3fmUhi ?
-
??During 2023 & 2024, we published several abstracts & posters at the most important scientific congresses, highlighting the advancement of eyonis? LCS, our end-to-end AI/ML tech-based CADe/CADx SaMD, reinforcing its future key role in supporting radiologists & pulmologists in lung cancer screening and LDCT image interpretation. ? ??Now, the most exciting part of our journey has just started with REALITY Standalone Pivotal Study that will be presented at 2025 ELCC and ATS congresses. Stay engaged and wait for our next post to know more and discover how we are marking another step toward innovation in medical imaging! #lungcancer #oncology #eyonis For more info about eyonis? visit our website: https://lnkd.in/dKAsXdS2
-
Spring is in the air in London today, and so is innovation! ? Following our new partnership with Medidata Solutions, Nicolas Dano, COO, and Laura Bertaina, Global Marketing Specialist, are attending Medidata NEXT London today! More than just a clinical trials conference, Medidata NEXT is an experience that brings together the greatest minds in life sciences—from pharma and biotech to medtech, CROs, and research sites. ? Looking forward to insightful discussions and making meaningful connections at the QEII Centre. See you there! #MedidataNEXT #ClinicalTrials #Innovation #LifeSciences?
-
-
Immuno-Oncology 360° is Around the Corner!??? The countdown is officially on—Median will be participating in IO360° next week! Swing by Booth #22?to: ???Discover?our central imaging services for oncology trials, backed by 100% dedication to oncology and extensive expertise across cancer indications, therapies, and imaging criteria. ???Explore?how we leverage cutting-edge AI-powered imaging intelligence to deliver actionable insights for biopharmaceutical companies, along with our radiopharmaceutical services and more! ???Connect?with Median's Imaging Specialists, Cyril Laurent and Connor Anderson, for insightful discussions. Want to schedule a meeting with us at IO360? Click here:?https://lnkd.in/eN4n5GWp See you next week at Booth #22! #IO3602025 #Oncology #AI #CancerResearch #LifeSciences?
-
-
??Since 2021, Median Technologies' eyonis? has conducted extensive R&D in the field of lung cancer, among other oncology indications, leading to eyonis? LCS, a high-performance Class II Software as a Medical Device candidate in 2025 for the specific indication of lung cancer screening. ??Now that we have successfully passed the Verification Study, the Standalone Pivotal Validation Study, and the MRMC Pivotal Validation Trial for eyonis? LCS, we also wanted to summarize all the scientific abstracts about our technology that we had presented to prestigious scientific societies. ??Indeed, between 2022 and 2025, 9 abstracts & posters were presented and accepted at leading oncology, pulmonology, and radiology congresses, reinforcing the scientific credibility of our technology. In 2022 alone, 4 abstracts were accepted, summarized in this carousel. Stay tuned for updates on our 2023, 2024 and 2025 abstracts, and we’re already looking forward to sharing more during this year! #lungcancer #oncology #eyonis For more info about eyonis? visit our website: https://lnkd.in/dKAsXdS2
-
Rejoignez-nous le 10 avril 2025 à 19h sur le campus EDHEC Paris pour une table ronde organisée par la Chaire Management in Innovative Health de l’EDHEC, sur l’IA au service des essais cliniques : opportunités, défis et positionnement de la France !
?? L’IA au service des essais cliniques – Opportunités, défis et positionnement de la France La Chaire Management in Innovative Health est très heureuse de vous convier à notre prochain évènement qui se tiendra le 10 avril 2025 à 19H sur le campus de l'Edhec Paris. L’intelligence artificielle redéfinit la recherche clinique et le développement de nouveaux traitements, ouvrant la voie à des essais plus rapides, plus précis et mieux adaptés aux patients. Comment ces technologies transforment-elles concrètement les pratiques médicales ? Quels sont les enjeux scientifiques, éthiques et réglementaires à surmonter ? Et surtout, quelle est la place de la France face à cette révolution technologique ? ?? Rejoignez-nous pour une table ronde exceptionnelle organisée par la chaire Management in Innovative Health de l’EDHEC Business School et Médian Technologies ?? 10 avril 2025 | ?? 19h | ?? Campus EDHEC Paris ?? Intervenants : ?? Olivier Clatz – Program Manager - Digital Ségur, Ministère des Solidarités et de la Santé ?? Antoine Iannessi – VP of Medical Affairs, Median Technologies ?? David Gruson – Directeur de Programme Santé à Domicile, La Poste Santé & Autonomie / Fondateur ETHIK-IA ?? Vassili Soumelis – Chief Medical Officer, Owkin ?? Modérateur de la session ?? Loick Menvielle?– Directeur Chaire Management in Innovative Health chez?EDHEC Business School ?? Au programme : Nos experts analyseront les avancées majeures de l’IA dans les essais cliniques et aborderont des questions essentielles : ? Comment l’IA permet-elle d’optimiser la conception des études cliniques et la sélection des patients ? ? Quels défis restent à relever en matière de qualité des données, de réglementation et d’éthique ? ? Comment la France peut-elle renforcer sa compétitivité face aux investissements massifs d’autres pays ? ?? Pourquoi participer ? ? Comprendre comment l’IA révolutionne les essais cliniques et la médecine personnalisée ? échanger avec des experts du domaine : chercheurs, industriels et régulateurs ? Identifier les opportunités et défis : avancées, contraintes réglementaires et enjeux éthiques ? évaluer la place de la France face aux acteurs internationaux ?? Inscription gratuite mais obligatoire ????https://lnkd.in/er-QH6DC ?? Ne manquez pas cette opportunité d’explorer l’avenir des essais cliniques avec l’IA ! #IA #Santé #EssaisCliniques #Innovation #MedTech #EDHEC #Median
-
#ELCC2025: Check out ????Dr. Raymond Osarogiagbon’s poster on "AI/ML-Based Lung Cancer Detection and Characterization for Lung Cancer Screening" where he will showcase the groundbreaking results of the REALITY study ????. We’re eager to share our innovations with you! Don’t hesitate to reach out ? https://lnkd.in/duqyaN5T #LungCancer #AI #MedicalDevices #Innovation #eyonis
-